ArticleCell death and differentiation2020
Global deletion of Optineurin results in altered type I IFN signaling and abnormal bone remodeling in a model of Paget's disease.
Article in Cell death and differentiation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Pooled it
- Artificial Intelligence-Assisted Structural Analysis of Bones with Paget's Disease of Bone and Osteoporosis: Lessons from Mouse Models.Diagnostics (Basel, Switzerland) · 2026Article
- Paget's disease of bone: pathogenesis, ocular manifestations, and therapeutic strategies.Orphanet journal of rare diseases · 2026Review
- Phase separation of OPTN initiates mitophagy to orchestrate craniofacial bone mineralization.Autophagy · 2026Article
- Optineurin modulates mTORC2/AKT/STAT3 signaling to control MHC class II expression and adaptive immunity against HSV-1.Cell reports · 2026Article
- Current advances of bone homeostasis imbalance in the cause of hereditary metabolic bone diseases.EFORT open reviews · 2026Review
- Melanoregulin Deficiency Affects Bone Maintenance and Lean Body Mass.bioRxiv : the preprint server for biology · 2025Article
- Intrinsically Disordered Regions of Zinc Finger Protein 687 in Phase Separation: A Potentially Pathogenic Driver of Paget's Disease of Bone.ACS pharmacology & translational science · 2025Review
- An emerging role of mitochondrial quality control in bone metabolism: from molecular mechanisms to targeted therapeutic interventions.Cellular and molecular life sciences : CMLS · 2025Review
- Preserving mitochondrial homeostasis protects against drug-induced liver injury via inducing OPTN (optineurin)-dependent Mitophagy.Autophagy · 2024Article
- Age-related effects of optineurin deficiency in the mouse eye.Vision research · 2024Article
- diABZI and poly(I:C) inhibit osteoclastic bone resorption by inducing IRF7 and IFIT3.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2024Article
- Caspase-4/11 promotes hyperlipidemia and chronic kidney disease-accelerated vascular inflammation by enhancing trained immunity.JCI insight · 2024Article
- Morphological multiparameter filtration and persistent homology in mitochondrial image analysis.PloS one · 2024Article
- Article
- Article
- Article
- Optineurin regulates NRF2-mediated antioxidant response in a mouse model of Paget's disease of bone.Science advances · 2023Article
- Systemic Dietary Hesperidin Modulation of Osteoclastogenesis, Bone Homeostasis and Periodontal Disease in Mice.International journal of molecular sciences · 2022Article
- The Paget's disease of bone risk gene PML is a negative regulator of osteoclast differentiation and bone resorption.Disease models & mechanisms · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Genome-wide association studies (GWAS) have identified Optineurin (OPTN) as genetically linked to Paget's disease of the bone (PDB), a chronic debilitating bone remodeling disorder characterized by localized areas of increased bone resorption and abnormal bone remodeling. However, only ~10% of mouse models with a mutation in Optn develop PDB, thus hindering the mechanistic understanding of the OPTN-PDB axis. Here, we reveal that 100% of aged Optn global knockout (Optn
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.